Fig. 6

CCL2 predicts response to immune checkpoint blockade therapy. A The expression pattern of 8 immune checkpoint genes in CCL2-high and CCL2-low GBM tissue. The statistical difference was calculated through the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001. B A heatmap of the correlation between CCL2 and multiple immune checkpoint genes in GBM, DLBC, LGG and UCS, as analyzed by the Spearman’s correlation analysis. * p < 0.05, ** p < 0.01. DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; LGG, brain lower grade glioma; UCS, uterine carcinosarcoma. C The number of patients responsive (true) or irresponsive (false) to the immune checkpoint blockade (ICB) therapy. D Boxplot representation of TIDE score in CCL2-high group versus CCL2-low in TCGA cohort. The statistical difference was calculated through the Wilcox test. * p < 0.05